Literature DB >> 1954811

Randomized trial comparing continuous subcutaneous insulin infusion and conventional insulin therapy in type II diabetic patients poorly controlled with sulfonylureas.

A M Jennings1, K S Lewis, S Murdoch, J F Talbot, C Bradley, J D Ward.   

Abstract

OBJECTIVE: To compare the effects of continuous subcutaneous insulin infusion (CSII) and conventional insulin therapy (CIT) in patients with poorly controlled sulfonylurea-treated diabetes mellitus. RESEARCH DESIGN AND METHODS: Twenty-five patients aged 40-65 yr and poorly controlled with sulfonylureas and without severe diabetic complications comprised the study group. Five patients left the study (3 achieved satisfactory glycemic control without insulin, 1 defaulted, 1 developed ketonuria). Ten patients were treated with CSII and 10 with CIT. Outpatient treatment consisted of CIT (twice-daily injections of regular and NPH insulin) or CSII (basal infusion and prandial boluses of regular insulin).
RESULTS: Glycosylated hemoglobin improved with both methods of insulin delivery (P less than 0.01), but 8 of 10 CSII-treated patients achieved satisfactory glycemic control (HbA1 less than 50 mmol hydroxymethylfurfural/mol Hb), whereas only 3 of 10 CIT-treated patients achieved this (P less than 0.05). Weight gain, insulin dosage, and prevalence of hypoglycemia were similar in the two groups. Retinal deterioration occurred in one CSII-treated patient and three CIT-treated patients, but there were no episodes of infusion site infection or metabolic decompensation. Patients' satisfaction with treatment improved during insulin therapy (P less than 0.02), and significant changes in beliefs about diabetes and its treatment were observed in CSII-treated patients (P less than 0.05).
CONCLUSIONS: Glycemic control improved with both methods of insulin treated patients achieved satisfactory glycemic control (HbA1 less than 50 mmol hydroxymethylfurfural/mol Hb), whereas only 3 of 10 CIT-treated patients achieved this CSII. Patients' satisfaction with treatment improved during insulin therapy.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1954811     DOI: 10.2337/diacare.14.8.738

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  7 in total

Review 1.  Insulin treatment in elderly patients with non-insulin-dependent diabetes mellitus. A double-edged sword?

Authors:  L Niskanen
Journal:  Drugs Aging       Date:  1996-03       Impact factor: 3.923

2.  Insulin pump use in type 2 diabetes.

Authors:  Bruce W Bode
Journal:  Diabetes Technol Ther       Date:  2010-06       Impact factor: 6.118

3.  The influence of insulin pump treatment on metabolic syndrome parameters in type 2 diabetes mellitus.

Authors:  Zdenek Jankovec; Daniela Cechurova; Michal Krcma; Silvie Lacigova; Michal Zourek; Zdenek Rusavy
Journal:  Wien Klin Wochenschr       Date:  2009       Impact factor: 1.704

4.  Efficacy, Safety and Treatment Satisfaction of Glimepiride vs Sitagliptin in Combination with Metformin in Type 2 Diabetes Mellitus.

Authors:  Subodh Kumar; Anuj Kumar Pathak; Dibyajyoti Saikia; Amish Kumar
Journal:  J Clin Diagn Res       Date:  2015-12-01

5.  Randomized trial of tofacitinib in active ulcerative colitis: analysis of efficacy based on patient-reported outcomes.

Authors:  Julián Panés; Chinyu Su; Andrew G Bushmakin; Joseph C Cappelleri; Carla Mamolo; Paul Healey
Journal:  BMC Gastroenterol       Date:  2015-02-05       Impact factor: 3.067

6.  Aspects of insulin treatment.

Authors:  Zachary T Bloomgarden
Journal:  Diabetes Care       Date:  2010-01       Impact factor: 19.112

7.  Lost in Translation: A Disconnect Between the Science and Medicare Coverage Criteria for Continuous Subcutaneous Insulin Infusion.

Authors:  Grazia Aleppo; Christopher G Parkin; Anders L Carlson; Rodolfo J Galindo; Davida F Kruger; Carol J Levy; Guillermo E Umpierrez; Gregory P Forlenza; Janet B McGill
Journal:  Diabetes Technol Ther       Date:  2021-06-17       Impact factor: 6.118

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.